⚠ Evidence warning: Clinical trials or other evidence do not support the claim that He Shou Wu improves memory or cognitive scores in older adults with mild cognitive impairment. This page keeps it as a report of what people, websites or other media say.

He Shou Wu for Cognitive Function

He shou wu vine in flower
He shou wu vine in flower
Processed black he shou wu slices
Processed black he shou wu slices

The cognitive and neuroprotective effects of He Shou Wu (Polygonum multiflorum) are among the most actively studied applications in the modern preclinical literature, with the active compound 2,3,5,4'-tetrahydroxystilbene-2-O-glucoside (TSG) producing measurable effects on amyloid-β toxicity, tau hyperphosphorylation, hippocampal neurogenesis, brain-derived neurotrophic factor (BDNF) expression, microglial inflammation, and cognitive performance in transgenic Alzheimer mouse models. The translational caveat is unavoidable: the data are preclinical — no human trial of He Shou Wu for memory or thinking has been published — and any cognitive benefit sits against the hepatotoxicity risk that the companion Liver Health and Hepatotoxicity Warning deep-dive details. This page walks through the cognitive mechanisms one by one, the state of the human evidence, the comparison with better-evidenced cognitive interventions, and where He Shou Wu sits among the components of an integrative cognitive-support plan.


Table of Contents

  1. TSG and Anti-Alzheimer Preclinical Data
  2. Amyloid-Beta Toxicity Reduction
  3. Tau Hyperphosphorylation Reduction
  4. Hippocampal Neurogenesis and Brain-Derived Neurotrophic Factor Upregulation
  5. Neuroinflammation and Microglial Phenotype
  6. Oxidative Stress in the Aging Brain
  7. The Human Evidence for Cognition
  8. Comparison with Other Cognitive Interventions
  9. Components of an Integrative Cognitive-Support Plan
  10. Cautions — Cognitive Use Carries the Same Hepatic Risk
  11. Key Research Papers
  12. Connections
  13. Featured Videos

TSG and Anti-Alzheimer Preclinical Data

The 2,3,5,4'-tetrahydroxystilbene-2-O-glucoside (TSG) molecule has accumulated one of the most extensive single-compound preclinical Alzheimer's disease evidence bases of any traditional Chinese medicine (TCM)-derived isolate. The model systems range from cell culture (PC12 neuronal cells, primary hippocampal neurons, SH-SY5Y human neuroblastoma cells) to transgenic mouse models (APP/PS1, 3xTg-AD, APP23 lines that overexpress mutant human amyloid precursor protein and develop amyloid plaques); no human trial has been published.

The consistent preclinical findings across these systems:

Two mouse studies show what this looks like in practice. In mice bred to develop Alzheimer-like changes (the PDAPPV717I line), TSG at 120 and 240 micromol/kg a day improved Morris water maze and object-recognition memory both when it was started early (from 4 months of age) and when it was started late (from 10 months of age) (Zhang et al., 2006). In APP/PS1 mice given TSG by stomach tube for 12 months from 5 months of age, amyloid deposits were reduced (Yin et al., 2018). These are animal results; no human trial has been published.

The mechanistic picture is that TSG is acting on multiple parallel pathways relevant to Alzheimer's pathophysiology rather than on a single target. This polypharmacology is characteristic of complex herbal compounds and is both a strength (multiple mechanisms may produce additive effect, less prone to single-pathway escape) and a weakness (harder to characterize precisely, harder to dose-optimize for a single endpoint).

The translational challenge is the same one faced by every Alzheimer preclinical signal: the mouse transgenic models reproduce some but not all features of the human disease, the dosing regimens used in mice are often not directly translatable to humans (some studies use the equivalent of grams per day in a human), and the human Alzheimer trials of compounds with strong preclinical signals (including the anti-amyloid antibodies until very recently) have a long history of disappointment.

The reasonable interpretation: TSG and He Shou Wu have a real and reproducible preclinical signal for cognitive protection and Alzheimer-relevant pathology reduction. This signal is suggestive but not yet established in humans. The strength of the preclinical evidence justifies continued investigation but does not justify positioning He Shou Wu as an established Alzheimer's prevention or treatment.

Back to Table of Contents

Amyloid-Beta Toxicity Reduction

The amyloid hypothesis of Alzheimer's disease — that abnormal aggregation of amyloid-β peptides (especially Aβ1-42) into oligomers, fibrils, and plaques drives downstream neurodegeneration — has been the dominant pathophysiologic framework for three decades. The 2021-2024 successes of anti-amyloid monoclonal antibodies (lecanemab, donanemab) in modestly slowing clinical decline in early Alzheimer's have partially validated the framework, though with safety costs (ARIA, the amyloid-related imaging abnormalities of cerebral edema and microhemorrhage).

TSG and He Shou Wu extracts have been shown to act on multiple steps of the amyloid pathway:

  1. Reduced amyloid production — in some studies, TSG modulates the activity or expression of α-secretase (non-amyloidogenic processing of amyloid precursor protein), β-secretase (BACE1, the rate-limiting amyloidogenic step), or γ-secretase, shifting APP processing away from the amyloidogenic pathway.
  2. Reduced amyloid aggregation — cell-culture studies show TSG can disrupt the secondary nucleation of amyloid oligomers, an effect shared with resveratrol and several other stilbene compounds.
  3. Reduced amyloid-induced neurotoxicity — when neurons are co-incubated with pre-formed amyloid-β oligomers (which are the most toxic species), TSG pre-treatment reduces the resulting calcium influx, mitochondrial dysfunction, and apoptosis.
  4. Enhanced amyloid clearance — some studies suggest TSG supports microglial phagocytosis of amyloid plaques in transgenic mouse models, contributing to reduced amyloid burden in chronically treated animals.
  5. Reduced amyloid plaque deposition in vivo — the integrated effect in APP/PS1 transgenic mice given 8 to 16 weeks of TSG is a 20 to 40% reduction in hippocampal and cortical amyloid plaque burden compared to vehicle-treated transgenic controls.

The magnitude of these effects in mice is comparable to what some early-development anti-amyloid drugs achieve, and notable in that TSG is achieving the effect without the ARIA safety signal that has limited the antibody drugs. The caveat is that mouse plaque models do not always predict human clinical efficacy.

Back to Table of Contents

Tau Hyperphosphorylation Reduction

The tau pathology of Alzheimer's disease — hyperphosphorylation of the microtubule-associated tau protein leading to its detachment from microtubules, aggregation into paired helical filaments, and formation of neurofibrillary tangles — correlates more strongly with cognitive decline than amyloid plaque burden in many human studies. Tau-targeted therapies are an active area of drug development, and the preclinical evidence for TSG and tau is among the more interesting parts of the He Shou Wu cognitive literature.

TSG has been shown to:

The GSK-3β effect is mechanistically the most interesting because GSK-3β is also implicated in mood disorders (lithium's antidepressant effect is partially attributed to GSK-3β inhibition) and in insulin signaling (GSK-3β is downstream of insulin receptor signaling, contributing to the "Type 3 diabetes" framing of Alzheimer's as a brain insulin-resistance condition). TSG's GSK-3β effect connects the cognitive benefits to the broader metabolic and inflammatory effects covered in the Longevity and Cardiovascular deep-dive.

Back to Table of Contents

Hippocampal Neurogenesis and Brain-Derived Neurotrophic Factor Upregulation

The adult mammalian hippocampus retains the capacity for neurogenesis — new neurons are generated from neural stem cells in the subgranular zone of the dentate gyrus throughout adult life, though the rate declines with age and is dramatically reduced in Alzheimer's disease and in chronic stress / depression. Restoring or enhancing hippocampal neurogenesis is a target of several emerging cognitive interventions.

TSG has been shown in rodent models to:

Brain-derived neurotrophic factor is one of the most extensively characterized molecules in cognitive neuroscience. It is required for long-term potentiation (LTP, the cellular correlate of learning and memory), for hippocampal-dependent memory consolidation, for the maturation and survival of new neurons, and for synaptic plasticity in adult cortex. Brain-derived neurotrophic factor expression is downregulated in depression, in chronic stress, in obesity, in metabolic syndrome, and in Alzheimer's disease. Interventions that upregulate brain-derived neurotrophic factor — including aerobic exercise (the strongest known brain-derived neurotrophic factor inducer), intermittent fasting, sleep, several antidepressants (the selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) class), and a growing number of natural compounds — tend to support cognitive function and mood.

TSG's brain-derived neurotrophic factor effect places it in this brain-derived neurotrophic factor-upregulating compound class, which also includes bacopa monnieri, lion's mane, curcumin, omega-3 fatty acids (eicosapentaenoic acid (EPA) in particular), and several flavonoids. The realistic clinical interpretation is that TSG is one of many possible levers for brain-derived neurotrophic factor support, not a uniquely potent one.

For broader context on cognitive support, see our pages on Bacopa Monnieri, Ginkgo Biloba, and the Alzheimer's Disease page.

Back to Table of Contents

Neuroinflammation and Microglial Phenotype

Chronic neuroinflammation — sustained low-grade activation of microglia and astrocytes, with elevated pro-inflammatory cytokines (interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α) and activation of NF-κB signaling — is now recognized as a central feature of Alzheimer's disease and probably a causal contributor rather than just a downstream response. The TREM2 gene, identified through Alzheimer genome-wide association studies (GWAS), codes for a microglial receptor; loss-of-function variants substantially increase Alzheimer risk and lock in this neuroinflammatory framework.

TSG and He Shou Wu extracts have well-characterized anti-neuroinflammatory effects:

The anti-neuroinflammatory mechanism is shared with several other neuroprotective natural compounds (curcumin, resveratrol, epigallocatechin gallate (EGCG), omega-3 eicosapentaenoic acid) and represents one of the more therapeutically interesting modes of action because it acts on a process that is causally upstream of both amyloid and tau pathology in some models.

Back to Table of Contents

Oxidative Stress in the Aging Brain

The brain is one of the organs most vulnerable to oxidative damage because of its high metabolic rate (the brain consumes approximately 20% of total body oxygen despite being 2% of body mass), high polyunsaturated fatty acid content in neuronal membranes (susceptible to lipid peroxidation), and relatively low endogenous antioxidant capacity (catalase is low in brain compared to liver). Cumulative oxidative damage to neurons, mitochondria, and DNA is implicated in the aging process and in several neurodegenerative diseases.

The TSG and broader stilbene-family antioxidant effects translate to brain tissue:

The Nrf2 pathway is mechanistically central here. Nrf2 (nuclear factor erythroid 2-related factor 2) is the master transcription factor for cellular antioxidant response. Under basal conditions, Nrf2 is sequestered in the cytoplasm by Keap1; under oxidative or electrophilic stress, Nrf2 translocates to the nucleus and induces dozens of antioxidant and detoxification genes (HO-1, NQO1, glutamate-cysteine ligase, glutathione synthase). TSG has been shown to activate the Nrf2 pathway in neuronal cell culture and in vivo, an effect shared with sulforaphane, curcumin, and several other neuroprotective natural compounds.

For more on oxidative stress and antioxidant biology, see our Oxidative Stress page.

Back to Table of Contents

The Human Evidence for Cognition

No human trial of Polygonum multiflorum or TSG for memory or thinking was found in PubMed. A 2024 review of the field (Cha et al.) gathered “preclinical research done on experimental models” — cell, mouse and rat studies — and presented them as “a basis for future clinical trials”. A double-blind placebo-controlled trial of TSG or a standardized Polygonum multiflorum extract in people with mild cognitive impairment is not yet available.

Back to Table of Contents

Comparison with Other Cognitive Interventions

Where does He Shou Wu fit in the broader landscape of cognitive interventions? Honest comparison requires acknowledging that the evidence base for He Shou Wu is preclinical-heavy, while the evidence base for several alternatives is human-trial-heavier. Relative position:

In summary: several interventions above have been tested in human trials, while He Shou Wu has been studied for cognition only in cells and animals, and it carries the liver-injury risk described in the cautions below.

Back to Table of Contents

Components of an Integrative Cognitive-Support Plan

The components that integrative cognitive-support plans layer together for an adult in their 60s or 70s with subjective memory complaints and mild objective cognitive testing decline, with where He Shou Wu sits among them:

  1. Modifiable cardiovascular risk — blood pressure, lipids, diabetes, smoking, weight, sleep apnea
  2. Aerobic exercise — the amount in public-health physical-activity guidelines is 150+ minutes per week of moderate-intensity activity, plus 2 sessions of resistance training
  3. Mediterranean-style diet — built on fish, leafy greens, olive oil, nuts and berries, with less ultra-processed food, refined carbohydrate and alcohol (see the MIND diet trial result above)
  4. Sleep — 7-8 hours, with sleep apnea and restless legs syndrome as the sleep disorders looked for
  5. Sensory deficits — hearing tests and hearing aids where hearing is lost (see the ACHIEVE result above), and vision checks
  6. Nutrient status — blood levels of B12, folate, vitamin D, omega-3 index, iron, and thyroid function
  7. Cognitive engagement — novel learning, social interaction, complex tasks (language learning, music, complex hobbies)
  8. He Shou Wu — studied for cognition only in cells and animals, so no human dose or cycle for cognitive use has been tested in a published trial; it carries the liver-injury risk described below.
  9. Adjacent better-evidenced cognitive herbs — Bacopa monnieri (a 12-week trial in adults aged 65 or older used 300 mg a day of standardized extract, Calabrese et al., 2008) and lion's mane mushroom (a 16-week trial in mild cognitive impairment used four 250 mg tablets three times a day, Mori et al., 2009), with much lower hepatotoxicity concern
  10. Regular cognitive testing — baseline and annual cognitive screening track the trajectory
  11. Specialist assessment — neurology and geriatrics clinics assess objective decline that progresses

The cognitive use of He Shou Wu carries the same hepatic risk profile as the hair-tonic use — a lower dose or a different reason for taking it is not known to reduce the idiosyncratic immune-mediated injury risk. The full hepatotoxicity warning applies.

Back to Table of Contents

Cautions — Cognitive Use Carries the Same Hepatic Risk

Back to Table of Contents

Key Research Papers

  1. Zhang L, Xing Y, Ye CF, Ai HX, Wei HF, Li L (2006). Learning-memory deficit with aging in APP transgenic mice of Alzheimer's disease and intervention by using tetrahydroxystilbene glucoside. Behav Brain Res 173(2):246-54. — PubMed PMID: 16901557
  2. Wang T, Yang YJ, Wu PF, et al. (2011). Tetrahydroxystilbene glucoside, a plant-derived cognitive enhancer, promotes hippocampal synaptic plasticity. Eur J Pharmacol 650(1):206-14. — PubMed PMID: 20951128
  3. Yin X, Chen C, Xu T, Li L, Zhang L (2018). Tetrahydroxystilbene glucoside modulates amyloid precursor protein processing via activation of AKT-GSK3β pathway in cells and in APP/PS1 transgenic mice. Biochem Biophys Res Commun 495(1):672-678. — PubMed PMID: 29129695
  4. Cha J, Yun JH, Choi JH, Lee JH, Choi BT, Shin HK (2024). Preclinical Evidence and Underlying Mechanisms of Polygonum multiflorum and Its Chemical Constituents Against Cognitive Impairments and Alzheimer's Disease. J Pharmacopuncture 27(2):70-81. — PubMed PMID: 38948308
  5. Liu W, Zeng X, Wang X, et al. (2024). 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucopyranoside (TSG)-Driven immune response in the hepatotoxicity of Polygonum multiflorum. J Ethnopharmacol 326:117865. — PubMed PMID: 38369066
  6. Livingston G, Huntley J, Liu KY, et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 404(10452):572-628. — PubMed PMID: 39096926
  7. Barnes LL, Dhana K, Liu X, et al. (2023). Trial of the MIND Diet for Prevention of Cognitive Decline in Older Persons. N Engl J Med 389(7):602-611. — PubMed PMID: 37466280
  8. Lin FR, Pike JR, Albert MS, et al. (2023). Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet 402(10404):786-797. — PubMed PMID: 37478886
  9. Calabrese C, Gregory WL, Leo M, et al. (2008). Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med 14(6):707-13. — PubMed PMID: 18611150
  10. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res 23(3):367-72. — PubMed PMID: 18844328

PubMed Topic Searches

  1. PubMed: Polygonum multiflorum cognition and Alzheimer's
  2. PubMed: TSG and amyloid-β
  3. PubMed: TSG and BDNF / hippocampal neurogenesis
  4. PubMed: Stilbene glycoside neuroprotection
  5. PubMed: Microglia M1/M2 and herbal anti-neuroinflammation

Back to Table of Contents

Connections

Back to Table of Contents